GlassScriptPhysician profile
Ayobamidele Saheed Balogun
NPI 1457871832
$1,162.77
in general payments reported to CMS, 2019-2025
18 companies · $428 in 2025
The $428 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $31.20 · 2022: $152 · 2023: $318 · 2024: $233 · 2025: $428.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $980.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $979.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $166.36 | 2024-2025 | Wegovy, Ozempic |
| Abbvie INC. | $161.56 | 2023-2025 | Dalvance, Teflaro |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $137.73 | 2023-2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $130.86 | 2023-2025 | Jardiance |
| Kestra Medical Technology Services, INC. | $123.12 | 2022 | |
| Novartis Pharmaceuticals Corporation | $93.00 | 2025 | |
| Pfizer INC. | $78.66 | 2021-2025 | |
| Medtronic, INC. | $59.78 | 2023 | |
| Amgen INC. | $47.13 | 2024-2025 | Repatha, Repatha |
| Kiniksa Pharmaceuticals, LTD. | $25.32 | 2022-2023 | Arcalyst |
| Lantheus Medical Imaging, INC. | $23.60 | 2023 | Definity |
| E.R. Squibb & Sons, L.L.C. | $19.11 | 2024 | Camzyos |
| Astrazeneca Pharmaceuticals LP | $17.93 | 2025 | Farxiga |
| Chiesi USA, INC. | $16.43 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $16.29 | 2023 | Evkeeza |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $16.25 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.07 | 2023 | |
| Esperion Therapeutics, INC. | $14.57 | 2025 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ayobamidele Balogun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.